Abs against CD47 such as Hu5F9-G4 (magrolimab) that block the CD47/SIRPα axis are in multiple clinical trials as a cancer immunotherapeutic in combination with other cancer therapeutics, including rituximab; have shown efficacy in certain human hematological cancers (21–25); and more recently have been shown to reduce inflammation in carotid arteries in a very small retrospective analysis of patient trial data (26). Here, CD47 is linked to hematopoietic and lymphoid cell neoplasm.